



SEMPERIT GROUP FY 2017 / Q4 2017 INVESTOR PRESENTATION

Dr Martin Füllenbach, CEO

Frank Gumbinger, CFO

16 March 2018



Transformation process initiated

Challenges and Timeline

Sempermed

- Cost efficiency / business model

Sempertrans

- Cost efficiency / production footprint

Group (1)

- Complex production footprint
- Capacity constraints in mixing

Group (2)

- Poor alignment of procurement / mixing / segments
- Limited data transparency / comparability

Timeline

- Transformation process started in late 2017
- Restructuring and transformation until 2020

Financial target

- ~10% EBITDA margin by end of 2020¹⁾

¹⁾ EBITDA margin target based on current segment structure.



Agenda

Operational highlights (p. 4)

Financial performance FY 2017 (p. 9)

Financial performance Q4 2017 (p. 14)

Management agenda 2018 (p. 22)

Appendix (p. 25)



2017 heavily impacted by one-off effects

Revenue +2.6% to € 874m	EBITDA +29% to € 100m Operating EBITDA € 36m ¹⁾	EBIT +38% to € 38m Operating EBIT € -1m ¹⁾
Positive one-off effect from JV transaction of 85m ²⁾ against negative effects of € 47m ²⁾	Earnings after tax € -26m No dividend proposed as restructuring and transformation started and as earnings after tax was negative	Raw material prices High volatility and procurement issues Mixing³⁾ Capacity constraints, need for additional external supply

¹⁾ EBITDA and EBIT adjusted for one-off effects.


²⁾ Positive one-off effect of € 85m from JV transaction, negative one-off effects of in total € 47m (thereof € 26m impairment at Sempermed segment, € 11m restructuring/plant closure in France, € 4m valuation adjustment in IT, € 5m expenses resulting from tax audit in Austria (mainly for refund of energy supply charge)).

³⁾ Mixing is responsible for preparing compounds used by all industrial segments; plants in Austria, Czech Rep., Germany, Poland, China, India, Thailand (for Semperflex JV).





Overview Semperflex and Sempertrans


FY 2017 vs. FY 2016



- Market demand up by 8-10%, solid increase of volumes sold
- Ramp up costs for new plant a burden
- Capacity increase in Czech Republic
- Encouraging profitability



- New market approach for North America
- Slight decrease of volumes
- Margin pressure due to global market overcapacity
- Loss-making
- French plant closed




¹⁾ EBIT for 2017 adjusted for expenses resulting from tax audit in Austria (mainly for refund of energy supply charge, € 1m).

²⁾ EBIT for 2017 adj. for expenses for restructuring / plant closure in France (€ 11m).




Overview Semperform and Sempermed


FY 2017 vs. FY 2016



- Encouraging volume development, mainly due to strong European demand
- Window and door profiles: strong expansion into aluminium windows
- Mixing capacity an issue
- Business performance not satisfying



- Competitive market environment with continuing margin pressure
- JV transaction with positive one-off effect
- State-of-the-art plant in Malaysia completed but efficiency of other plants not sufficient
- Partial production interruptions
- Still loss making at operating level



¹⁾ EBIT 2017 adjusted for expenses resulting from tax audit in Austria (mainly for refund of energy supply charge, € 2m).

²⁾ EBIT 2017 adjusted for positive one-off from JV transaction (€ 78m in Q1 2017), for impairment (€ 26m in Q2 2017) and for expenses from tax audit in Austria (mainly for refund of energy supply charge, € 2m). EBIT 2016 without profit contribution from SSC, impairment and one-off effect trade tax / levies in Brazil.




Investments at a glance

Investment Overview


- **Capex 2017** of € 75m, thereof maintenance € ~30m
- **Capex 2018** of € ~80m expected
- Thereof about 60% **for expansion**:
 - 45% for further Semperflex expansion Czech Rep.
 - 35% for further mixing expansion mainly in Poland
 - ▶ Both projects initiated in 2015 and since then gradually implemented
 - 20% for other segments

Capex and depreciation


in EUR m



Total Capex split FY 2018



Expansion Capex split FY 2018





Agenda

Operational highlights (p. 4)

Financial performance FY 2017 (p. 9)

Financial performance Q4 2017 (p. 14)

Management agenda 2018 (p. 22)

Appendix (p. 25)



FY 2017 Financials / Profitability Overview

Key Financials Semperit Group			
in EUR m	2017	2016	%
Revenue	874.2	852.4	+2.6%
EBITDA	100.2	77.9	+28.6%
<i>Adj. EBITDA / Operating EBITDA¹⁾</i>	35.8	74.7	-52.1%
EBIT	37.6	27.3	+37.8%
<i>Adj. EBIT / Operating EBIT¹⁾</i>	-0.8	41.1	-
Earnings after tax²⁾	-26.3	-8.8	> 100%
<i>Adj. Earnings after tax^{1) 3)}</i>	-43.3	15.2	-
Profitability			
EBITDA margin	11.5%	9.1%	+2.4 PP
EBIT margin	4.3%	3.2%	+1.1PP
Earnings per share in EUR³⁾	-1.25	-0.43	> 100%


¹⁾ Figures for 2016 without profit contribution from SSC, one-off effect trade tax / levies in Brazil (for EBITDA and EBIT) and impairment Sempermed (for EBIT only). Figures for 2017 adjusted for positive one-off effects from JV transaction (€ 85m in Q1 2017), for impairment at Sempermed (€ 26m in Q2 2017, only for EBIT), for expenses resulting from tax audit in Austria (5m, mainly for refund of energy supply charge), expenses for restructuring / plant closure in France (€ 11m) and for valuation adjustment IT (€ 4m).

²⁾ Earnings after tax in FY 2017 negatively impacted by higher expenses for income taxes due to JV transaction, value adjustment of deferred taxes and non-recognised deferred tax assets. ³⁾ Attributable to the shareholders of Semperit AG Holding.



Revenue development FY 2017 vs FY 2016

in EUR m



Revenue development

- Semperflex: mainly higher volume translates into higher revenue
- Sempertrans: revenue almost stable despite decrease of volume and price pressure from competition
- Semperform: volume growth in all business units
- Sempermed: decrease of volume sold in examination gloves, increase in surgical gloves; some support from price increases


Revenue in FY 2017 ► 206.1m 146.0m 185.0m 337.1m

¹⁾ Change of each segment / sector for FY 2017 vs 2016




From reported to operating EBIT FY 2017

in EUR m





Operating EBIT FY 2017 vs FY 2016¹⁾



	FY 2016	Semperflex	Sempertrans	Semperform	Sempermed	Corporate	FY 2017
Operating EBIT FY 2016 ¹⁾	41.1m	35.3m	12.1m	22.5m	-10.1m	-18.7m	
Operating EBIT FY 2017 ²⁾		32.7m	-8.9m	13.3m	-12.1m	-25.8m	-0.8m
Operating EBIT margin FY 2017 ¹⁾		15.9%	-6.1%	7.2%	-3.6%	n/a	-0.1%

¹⁾ Figures for 2016 without profit contribution from SSC, impairment Sempermed and trade tax / levies in Brazil. ²⁾ Figures for FY 2017 adjusted effects from JV transaction for impairment at Sempermed (€ 26m), restructuring expenses in France (€ 11m), expenses resulting from tax audit in Austria (€ 5m, mainly for refund of energy supply charge).



Agenda

Operational highlights (p. 4)

Financial performance FY 2017 (p. 9)

Financial performance Q4 2017 (p. 14)

Management agenda 2018 (p. 22)

Appendix (p. 25)



Q4 2017 Financials / Profitability Overview

Key Financials Semperit Group

in EUR m	Q4 2017	Q4 2016	%
Revenue	204.2	204.8	-0.3%
EBITDA	2.4	5.7	-57.9%
<i>Adj. EBITDA / Operating EBITDA¹⁾</i>	2.9	7.2	-59.9%
EBIT	-8.5	-19.3	-56.0%
<i>Adj. EBIT / Operating EBIT¹⁾</i>	-8.7	-0.9	> 100%
Earnings after tax²⁾	-31.1	-32.1	-3.2%
<i>Adj. Earnings after tax^{1) 3)}</i>	-29.7	4.4	–
Profitability			
EBITDA margin	1.2%	2.8%	-1.6 PP
EBIT margin	-4.2%	-9.4%	+5.2 PP
Earnings per share in EUR²⁾	-1.49	-1.57	+5.1%

¹⁾ Figures for Q4 2016 without profit contribution from SSC, impairment Sempermed and trade tax / levies in Brazil, total negative effect (on EBIT) of € 18.4m, and tax effect from JV transaction.


²⁾ Earnings after tax in Q4 2017 negatively impacted by higher expenses for income taxes due to impairment of deferred taxes and non-recognised deferred tax assets.

³⁾ Attributable to the shareholders of Semperit AG Holding.



Revenue development Q4 2017 vs Q4 2016

in EUR m




¹⁾ Change of each segment / sector for Q4 2017 vs Q4 2016




Revenue by quarter


in EUR m



Revenue by region FY 2017 (FY 2016)




Revenue by segment FY 2017 (FY 2016)



¹⁾ 2016 values adjusted: reclassification of the business unit Sheeting from Semperflex to Semperform segment.



Operating EBIT and EBIT margin by quarter¹⁾



EBIT development


- Operating EBIT not satisfying at all in Q4 2017, negatively impacted by
 - Lower profitability in Sempermed as a result of partial interruption in production and depreciation of glove formers
 - Provision for customer claims
 - Expenses for external support for restructuring and transformation
- Semperfex and Semperform with continuous positive EBIT contribution
- Sempertrans and Sempermed still loss-making in Q4 2017 at EBIT level

¹⁾ Figures for 2016 without profit contribution from SSC, impairment Sempermed and trade tax / levies in Brazil.

Figure for Q1 2017 adjusted for positive one-off effects from JV transaction (€ 85m), figure for Q2 2017 adjusted for impairment at Sempermed (€ 26m), restructuring expenses in France (7m in Q2) and valuation adjustment in IT (€ 4m). Figure for Q3 2017 adjusted for expenses resulting from tax audit in Austria (€ 5m, mainly for refund of energy supply charge) as well as restructuring expenses in France (€ 5m in Q3).



Operating EBIT Q4 2017 vs Q4 2016¹⁾



	Q4 2016	Semperfex	Sempertrans	Semperform	Sempermed	Corporate	Q4 2017
Operating EBIT in Q4 2016 ▶	8.4m	0.5m	4.0m	-4.6m	-9.1m		
Operating EBIT in Q4 2017 ▶	7.8m	-3.1m	1.3m	-6.6m	-8.1m		
Operating EBIT margin in Q4 2017 ▶	14.8%	-9.6%	3.0%	-8.6%	n/a		


¹⁾ Figures for Q4 2016 without profit contribution from SSC, impairment Sempermed and trade tax / levies in Brazil



CAPEX and Working Capital Overview

CAPEX per Segment


in EUR m



CAPEX FY 2017 total: € 74.5m

Components of Working Capital

in EUR m




¹⁾ Trade Working Capital in % of LTM revenues



Net debt significantly reduced

Balance sheet structure 31 December 2017

Balance sheet total: EUR 853 m



Financial profile as of 31 December 2017

- Cash and cash equivalents of EUR 166m
- Financial liabilities:
 - Corporate Schuldschein loan of EUR 270m
 - Liabilities to banks of EUR 57m
- Net debt of EUR 161m
 - down by EUR 70m since end of Dec. 2016
 - Net debt / EBITDA of 1.61x, compared to 2.96x as of end of Dec. 2016
- Equity ratio of 32.6%, compared to 31.8% as of end of Dec. 2016



Agenda

Operational highlights (p. 4)

Financial performance FY 2017 (p. 9)

Financial performance Q4 2017 (p. 14)

Management agenda 2018 (p. 22)

Appendix (p. 25)



Management agenda for 2018: Restructuring and Transformation

Production footprint / business unit portfolio

- step by step decisions and modifications

Operational Excellence

- Improvement of pricing / price setting processes
- Focus on execution / competitive edge in procurement

Operations

- Optimisation of production (“World Class Manufacturing”)

Investments

- Overall Capex of EUR 80m for FY 2018
- About half for expansion of Semperflex and mixing

Financial impact

- Further significant one-off charges possible
- Outlook remains suspended for coming quarters



Contact and financial calendar

Investor Relations Semperit Group

Stefan Marin, Head of Investor Relations

+43 1 79777 - 210

www.semperitgroup.com/en/ir

Modecenterstrasse 22

1031 Vienna, Austria

Financial Calendar 2018

16.03.2018	Publication of 2017 annual financial statements
15.04.2018	Record date of the Annual General Meeting
25.04.2018	Annual General Meeting
02.05.2018	Dividend ex day ¹⁾
04.05.2018	Dividend payment day ¹⁾
25.05.2018	Report on the first quarter of 2018
23.08.2018	Half-year financial report 2018
21.11.2018	Report on the first three quarters 2018

¹⁾ No dividend proposed for FY 2017 to AGM on 25.04.2018

Disclaimer

The information provided in this presentation does not constitute an offer for the sale of securities nor an invitation to submit an offer to purchase shares of Semperit AG Holding, but exclusively serves information purposes. Rounding of differences in the totalling of rounded amounts and percentages may arise from the automatic processing of data.

The forecasts, plans and forward-looking statements contained in this presentation are based on the knowledge and information available and the assessments made at the time that this report was prepared. As is true of all forward-looking statements, these statements are subject to risk and uncertainties. As a result, the actual events may deviate significantly from these expectations. No liability whatsoever is assumed for the accuracy of projections or for the achievement of planned targets or for any other forward-looking statements.



Agenda

Operational highlights (p. 4)

Financial performance FY 2017 (p. 9)

Financial performance Q4 2017 (p. 14)


Management agenda 2018 (p. 22)

Appendix (p. 25)



Overview price indices rubber

Price movements for raw materials¹⁾ became highly unpredictable



¹⁾ Selected raw materials are shown for illustration purposes only. Indices based on 01/01/2016 = 100



Hybrid Capital Line with B & C

- **Overview**

- Contract between Semperit AG Holding and B & C Holding GmbH (100% subsidiary of B & C Industrieholding GmbH) signed on 12th Dec. 2017
Total volume of up to EUR 150m
- Can be drawn in up to three tranches until end of 2018
- Interest rate agreed amounts to 5.25%,
commitment fee (for unused part of the line) is set at 1.75%

- **Benefits for Semperit**

- Financial support for transformation process
- Strengthening of balance sheet

The core shareholder supports the transformation process and emphasises its long-term commitment to Semperit.



Sectors and Group: FY 2017 vs FY 2016

in EUR m	Industrial Sector			Medical Sector			Semperit Group ¹⁾		
	2017	2016	%	2017	2016	%	2017	2016	%
Revenue	537.0	506.4	+6.0%	337.1	346.0	-2.6%	874.2	852.4	+2.6%
EBITDA	42.9	89.5	-52.0%	77.9	6.6	> 100%	100.2	77.9	+28.6%
EBITDA margin	8.0%	17.7%	-9.7 PP	23.1%	1.9%	+21.2 PP	11.5%	9.1%	+2.4 PP
Adj. EBITDA²⁾	57.6	89.5	-35.6%	1.8	3.4	-48.5%	35.8	74.7	-52.1%
Adj. EBITDA margin²⁾	10.7%	17.7%	-7.0 PP	0.5%	1.0%	-0.5 PP	4.1%	8.8%	-4.7 PP
EBIT	22.4	70.0	-67.9%	38.0	-23.9	–	37.6	27.3	+37.8%
EBIT margin	4.2%	13.8%	-9.6 PP	11.3%	-6.9%	+18.2 PP	4.3%	3.2%	+1.1 PP
Adj. EBIT²⁾	37.1	70.0	-47.0%	-12.1	-10.1	+19.5%	-0.8	41.1	–
Adj. EBIT margin²⁾	6.9%	13.8%	-6.9 PP	-3.6%	-2.9%	-0.7 PP	-0.1%	4.8%	-4.9 PP
Earnings after Tax	–	–	–	–	–	–	-26.3	-8.8	> 100%
Adj. Earnings after tax²⁾	–	–	–	–	–	–	-43.3	15.2	–
Earnings per share in EUR³⁾	–	–	–	–	–	–	-1.25	-0.43	> 100%
Investments	48.5	34.9	+39.0%	25.3	25.7	-1.6%	74.5	65.1	+14.5%
Employees	3,648	3,637	+0.3%	3,051	3,183	-4.2%	6,838	6,974	-1.9%

¹⁾ Including Corporate Center costs (Holding, supporting functions, special projects): € -22.8m in FY 2017 (€ -18.7m in FY 2016).

²⁾ Adj. EBIT: Figures for 2016 without profit contribution from SSC and adjusted for one-off effect trade tax / levies in Brazil and impairment Sempermed. Figures for FY 2017 adjusted for positive one-off effects from JV transaction (€ 85m), impairment at Sempermed (€ 26m), restructuring expenses in France (€ 11m), valuation adjustment in IT (€ 4m) and expenses resulting from tax audit in Austria (€ 5m, mainly for refund of energy supply charge). ³⁾ Attributable to shareholders of Semperit AG Holding



Sectors and Group: Q4 2017 vs Q4 2016

In EUR m	Industrial Sector			Medical Sector			Semperit Group ¹⁾		
	2017	2016	%	2017	2016	%	2017	2016	%
Revenue	127.3	117.1	8.7%	76.9	87.6	-12.3%	204.2	204.8	-0.3%
EBITDA	11.9	17.7	-32.7%	-1.6	-3.2	-50.6%	2.4	5.7	57.9%
EBITDA margin	9.4%	15.1%	-5.7 PP	-2.0%	-3.6%	+1.6 PP	1.2%	2.8%	-1.6 PP
Adj. EBITDA²⁾	12.0	17.7	32.4%	-1.5	-1.7	-10.0%	2.9	7.2	-59.9%
Adj. EBITDA margin²⁾	9.4%	15.1%	-5.7 PP	-2.0%	-2.0%	0.0 PP	1.4%	3.5%	-2.1 PP
EBIT	5.9	12.8	-53.7%	-6.7	-23.1	-71.0%	-8.5	-19.3	-56.0%
EBIT margin	4.7%	11.0%	-6.3 PP	-8.7%	-26.3%	+17.6%	-4.2%	-9.4%	+5.2 PP
Adj. EBIT²⁾	6.0	12.8	-53.5%	-6.6	-4.6	44.6%	-8.7	-0.9	> 100%
Adj. EBIT margin²⁾	4.7%	11.0%	-6.3 PP	-8.6%	-5.3%	-3.3 PP	-4.3%	-0.4%	-3.9 PP
Earnings after Tax	–	–	–	–	–	–	–	–	–
Adj. Earnings after tax²⁾	–	–	–	–	–	–	–	–	–
Earnings per share in EUR³⁾	–	–	–	–	–	–	–	–	–
Investments	11.5	13.6	-15.4%	7.1	7.2	-1.4%	18.6	20.8	-10.6%
Employees	3,648	3,637	+0.3%	3,051	3,183	-4.2%	6,838	6,974	-1.9%

¹⁾ Including Corporate Center costs (Holding, supporting functions, special projects): € -7.7m in Q4 2017 (€ -9.0m in Q4 2016).

²⁾ Figures for EBIT 2016 without profit contribution from SSC and adjusted for one-off effect trade tax / levies in Brazil and impairment Sempermed.

³⁾ Attributable to shareholders of Semperit AG Holding



Semperit Group per quarter as reported

Semperit Group (reported)

in EUR m	FY 2014 ¹⁾	FY 2015 ¹⁾	Q1 2016	Q2 2016	Q3 2016	Q4 2016	FY 2016	Q1 2017	Q2 2017	Q3 2017	Q4 2017	FY 2017
Revenue	858.3	914.7	219.5	219.2	208.9	204.8	852.4	229.3	232.3	208.4	204.2	874.2
EBITDA	101.9	96.2	26.7	26.1	19.4	5.7	77.9	94.4	2.9	0.5	2.4	100.2
EBITDA margin	11.9%	10.5%	12.2%	11.9%	9.3%	2.8%	9.1%	41.2%	1.2%	0.2%	1.2%	11.5%
EBIT	63.8	66.7	18.6	17.6	10.4	-19.3	27.3	86.4	-32.0	-8.2	-8.5	37.6
EBIT margin	7.4%	7.3%	8.5%	8.0%	5.0%	-9.4%	3.2%	37.7%	-13.8%	-3.9%	-4.2%	4.3%
Financial result	-11.5	-8.0	-5.9	-4.1	-2.7	-7.2	-19.9	-8.0	-6.5	-6.1	-4.9	-25.5
Earnings after tax	37.8	46.4	10.1	7.7	5.5	-32.1	-8.8	62.8	-41.6	-16.4	-31.1	-26.3
Earnings per share in EUR²⁾	1.85	2.26	0.49	0.38	0.27	-1.57	-0.43	3.06	-2.02	-0.79	-1.49	-1.25

¹⁾ Values for 2014 and 2015 restated

²⁾ Attributable to shareholders of Semperit AG Holding




Semperit Group adj. where applicable


Semperit Group adj. where applicable

in EUR m	FY 2014 ¹⁾	FY 2015 ¹⁾	Q1 2016 adj. ²⁾	Q2 2016 adj. ²⁾	Q3 2016 adj. ²⁾	Q4 2016 adj. ²⁾	FY 2016 adj. ²⁾	Q1 2017 adj. ³⁾	Q2 2017 adj. ⁴⁾	Q3 2017 adj. ⁴⁾	Q4 2017 adj. ⁴⁾	FY 2017 adj.
Revenue	858.3	914.7	219.5	219.2	208.9	204.8	852.4	229.3	232.3	208.4	204.2	874,2
EBITDA	101.9	96.2	24.6	25.5	17.4	7.2	74.7	9.6	12.9	10.4	2.9	35.8
EBITDA margin	11.9%	10.5%	11.2%	11.7%	8.3%	3.5%	8.8%	4.2%	5.6%	5.0%	1.4	4.1%
EBIT	63.8	66.7	16.5	17.1	8.4	-0.9	41.1	1.6	4.6	1.7	-8.7	-0.8
EBIT margin	7.4%	7.3%	7.5%	7.8%	4.0%	-0.4%	4.8%	0.7%	2.0%	0.8%	-4.3	-0.1%

EBITDA adj. per quarter



EBIT adj. per quarter



¹⁾ Values for 2014 and 2015 restated


²⁾ Adj. for negative one-off effects in Q4 2016 and without profit contribution from SSC for FY 2016 ³⁾ Q1 2017 adj. for positive one-off effects from JV transaction of 85m

⁴⁾ Q2, Q3 and Q4 2017 adj. for impairment at Sempermed (€ 26m), restructuring expenses/closure in France (€ 11m) and valuation adjustment in IT (€ 4m), expenses resulting from tax audit in Austria (€ 5m, mainly for refund of energy supply charge).




EBIT adj. per Segment per Quarter


Semperflex




Sempertrans



Semperform



Sempermed





Semperflex and Sempertrans (adj. where applicable)

Semperflex

in EUR m	FY 2014 ¹⁾	FY 2015 ¹⁾	Q1 2016 adj. ²⁾	Q2 2016 adj. ²⁾	Q3 2016 adj. ²⁾	Q4 2016 adj. ²⁾	FY 2016 adj. ²⁾	Q1 2017	Q2 2017	Q3 2017 adj. ³⁾	Q4 2017 adj. ³⁾	FY 2017 adj.
Revenue	202.1	203.4	47.8	48.8	43.4	44.9	184.9	53.5	53.2	46.8	52.5	206.1
EBITDA	48.5	46.1	11.8	12.5	8.8	10.3	43.4	11.7	10.5	8.7	10.5	41.4
EBITDA margin	24.0%	22.7%	24.7%	25.7%	20.2%	22.9%	23.5%	21.8%	19.8%	18.6%	19.9%	20.1%
EBIT	36.8	38.2	9.7	10.5	6.7	8.4	35.3	9.6	8.6	6.8	7.8	32.7
EBIT margin	18.2%	18.8%	20.4%	21.5%	15.5%	18.6%	19.1%	18.0%	16.1%	14.5%	14.8%	15.9%

Sempertrans

in EUR m	FY 2014 ¹⁾	FY 2015 ¹⁾	Q1 2016	Q2 2016	Q3 2016	Q4 2016	FY 2016	Q1 2017	Q2 2017 adj. ⁴⁾	Q3 2017 adj. ⁴⁾	Q4 2017 adj. ⁴⁾	FY 2017 adj.
Revenue	146.4	164.9	42.6	38.9	32.7	34.1	148.4	41.3	36.8	35.7	32.1	146.0
EBITDA	20.9	23.2	5.8	5.7	3.0	1.4	15.9	0.6	-2.4	-1.4	-2.1	-5.3
EBITDA margin	14.3%	14.0%	13.6%	14.5%	9.2%	4.1%	10.7%	1.4%	-6.4%	-3.9%	-6.6%	-3.6%
EBIT	16.8	19.9	4.8	4.7	2.1	0.5	12.1	-0.3	-3.3	-2.2	-3.1	-8.9
EBIT margin	11.5%	12.1%	11.3%	12.1%	6.3%	1.5%	8.2%	-0.8%	-8.9%	-6.3%	-9.6%	-6.1%

¹⁾ Values for 2014 and 2015 restated ²⁾ Values for 2016 restated, the business unit Sheeting was reclassified from segment Semperflex to segment Semperform

³⁾ Adj. for expenses resulting from tax audit in Austria, mainly for refund of energy supply charge, (€ 1m)

⁴⁾ Adj. for restructuring expenses/closing in France (€ 11m for EBIT)



Semperform and Sempermed (adj. where applicable)

Semperform												
in EUR m	FY 2014 ¹⁾	FY 2015 ¹⁾	Q1 2016 adj. ²⁾	Q2 2016 adj. ²⁾	Q3 2016 adj. ²⁾	Q4 2016 adj. ²⁾	FY 2016 adj. ²⁾	Q1 2017	Q2 2017	Q3 2017 adj. ⁶⁾	Q4 2017 adj. ⁶⁾	FY 2017 adj.
Revenue	129.0	152.8	43.2	47.6	44.3	38.1	173.1	45.3	50.1	46.9	42.7	185.0
EBITDA	18.6	24.3	7.4	9.1	7.6	6.1	30.2	5.0	7.8	5.2	3.6	21.5
EBITDA margin	14.5%	15.9%	17.2%	19.0%	17.3%	16.0%	17.4%	10.9%	15.5%	11.0%	8.5%	11.6%
EBIT	12.7	19.1	5.7	7.2	5.7	4.0	22.5	3.0	5.8	3.2	1.3	13.3
EBIT margin	9.9%	12.5%	13.1%	15.2%	12.8%	10.4%	13.0%	6.6%	11.5%	6.8%	3.0%	7.2%

Sempermed												
in EUR m	FY 2014 ¹⁾	FY 2015 ¹⁾	Q1 2016 adj. ³⁾	Q2 2016 adj. ³⁾	Q3 2016 adj. ³⁾	Q4 2016 adj. ³⁾	FY 2016 adj. ³⁾	Q1 2017 adj. ⁴⁾	Q2 2017 adj. ⁵⁾	Q3 2017 adj. ⁶⁾	Q4 2017 adj.	FY 2017 adj.
Revenue	380.8	393.7	85.9	83.8	88.6	87.6	346.0	89.2	92.2	78.8	76.9	337.1
EBITDA	33.5	29.4	4.0	1.3	-0.1	-1.7	3.4	0.0	1.7	1.6	-1.5	1.8
EBITDA margin	8.8%	7.5%	4.6%	1.6%	-0.2%	-2.0%	1.0%	±0.0%	1.9%	2.0%	-2.0%	0.5%
EBIT	17.6	17.2	0.8	-2.2	-4.1	-4.6	-10.1	-2.8	-1.2	-1.5	-6.6	-12.1
EBIT margin	4.6%	4.4%	0.9%	-2.6%	-4.6%	-5.3%	-2.9%	-3.1%	-1.3%	-1.8%	-8.6%	-3.6%

¹⁾ Values for 2014 and 2015 restated ²⁾ Values for 2016 restated, the business unit Sheeting was reclassified from segment Semperflex to segment Semperform

³⁾ Adj. for negative one-off effects in Q4 2016 and without profit contribution from SSC for FY 2016

⁴⁾ Q1 2017 Sempermed adj. for positive one-off effects from JV transaction in Q1 2017 of 78m for EBIT ⁵⁾ Q2 2017 adj. for impairment at Sempermed (26m)

⁶⁾ Adj. for expenses resulting from tax audit in Austria, mainly for refund of energy supply charge (€ 2m for Semperform, € 2m for Sempermed)



Key figures 2008 – 2017

Key performance figures

in EUR m	2008	2009	2010 ¹⁾	2011 ¹⁾	2012	2013	2014 ³⁾	2015 ³⁾	Adj. 2016 ⁴⁾	Adj. 2017 ⁵⁾
Revenue	655.3	588.1	689.4	820.0	828.6	906.3	858.3	914.7	852.4	874.2
EBITDA	87.9	102.8	112.3	110.0	108.7	132.5	101.9	96.2	74.7	35.8
EBITDA margin	13.4%	17.5%	16.3%	13.4%	13.1%	14.6%	11.9%	10.5%	8.80%	4.10%
EBIT	58.7	69.6	82.3	80.4	72.5	87.8	63.8	66.7	41.1	-0.8
EBIT margin	9.0%	11.8%	11.9%	9.8%	8.8%	9.7%	7.4%	7.3%	4.80%	-0,1%
Earnings after tax	44.9	38.8	45.4	51.8	46.2	54.9	37.8	46.4	15.2	-43.9
Earnings per share (EPS) ²⁾ , in EUR	1.83	1.89	2.21	2.52	2.25	2.65	1.85	2.26	0.74	-2.13
Gross cash flow	78.0	92.6	91.0	89.4	85.6	116.2	89.9	55.7		32.2
Return on equity	12.9%	12.5%	12.9%	13.6%	11.4%	13.3%	8.6%	12.8%	4.6%	-15.8%

Balance sheet key figures

in EUR m	2008	2009	2010 ¹⁾	2011 ¹⁾	2012	2013	2014 ³⁾	2015 ³⁾	2016	2017
Balance sheet total	485.5	531.5	593.5	616.7	824.5	852.1	826.3	937.8	1,034.5	853.2
Equity ²⁾	291.9	310.6	351.1	379.4	406.2	411.5	443.8	363.3	329.3	278.5
Equity ratio	60.1%	58.4%	59.2%	61.5%	49.3%	48.3%	53.7%	38.7%	31.8%	32.6%
Investments in tangible and intangible assets	27.6	22.7	52.5	45.1	41.2	49.7	67.4	71.8	65.1	74.5
Employees (at balance sheet date)	7,064	6,649	7,019	8,025	9,577	10,276	6,888	7,053	6,974	6,838

¹⁾ Values for 2011 restated (see Annual Report 2012, Notes 2.18), values for 2010 not restated. ²⁾ Attributable to shareholders of Semperit AG Holding.


³⁾ Values for 2014 and 2015 restated. ⁴⁾ Figures for 2016 without profit contribution from SSC, impairment Sempermed and trade tax / levies in Brazil

⁵⁾ Figures for FY 2017 adjusted for positive one-off effects from JV transaction (€ 85m), impairment at Sempermed (€ 26m, only for EBIT), expenses resulting from tax audit in Austria (€ 5m, mainly for refund of energy supply charge), expenses for restructuring / plant closure in France (€ 11m) and for valuation adjustment IT (€ 4m).



Shareholder Structure

Shareholder structure



- Semperit is listed on the Vienna Stock Exchange since 1890
- Total of 20,573,434 shares with a market capitalization of more than EUR 300m (mid March 2018)
- B & C Holding Österreich GmbH is part of B & C Privatstiftung, an Austrian based private foundation / trust
- Primary focus of B & C is pursuing the foundation's mission to "foster Austrian entrepreneurship"
- Semperit benefits from a supportive ownership structure with long-term commitment from B & C
- Fidelity Management and Research is an American multinational financial services corporation